Exscientia to present new preclinical data for ai-designed lsd1 and malt1 inhibitors at ena 2024

Oxford, england--(business wire)--exscientia plc (nasdaq: exai) today announced three abstracts to be presented at the 36th eortc-nci-aacr (ena) symposium 2024 from october 23-25, in barcelona, spain. “as our precision-designed lsd1 and malt1 inhibitors continue to progress towards the clinic, we are excited to share new preclinical data from both programmes,” said david hallett, ph.d., interim chief executive officer and chief scientific officer of exscientia. “these posters, as well as an add.
EXAI Ratings Summary
EXAI Quant Ranking